Cytocom, a biopharmaceutical company in the area of immune-modulation, completed the merger with Cleveland BioLabs, a biopharmaceutical company developing novel approaches to activate the immune system. Financial terms were not disclosed. Cytocom shareholders have a majority position in the newly combined entity, which the parties anticipate continue to be listed on the Nasdaq. "Our merger with Cleveland BioLabs and its subsequent immune-focused platform will be a transformative growth opportunity for Cytocom and Cleveland BioLabs shareholders. We believe that the combination of these highly complementary late-stage pipelines will strengthen our position and advance our efforts to unlock the potential of immune-modulating agents in the treatment of serious medical conditions. Further, this merger will enhance our ability to become a recognized leader in immune-modulating treatments and builds on the momentum created by our recent acquisition of ImQuest Life Sciences. We plan to utilize the combined platform to further drive value with additional clinical and commercial products and continue to seek strategic partnerships and acquisitions," Michael K. Handley, Cytocom President and CEO.